Synonyms: DSP-5336 | DSP5336
Compound class:
Synthetic organic
Comment: Enzomenib (DSP-5336) a is small-molecule menin inhibitor [1]. It binds to the nuclear tumour suppressor protein menin (MEN1) and prevents its interaction with menin-mixed lineage leukemia (MLL; KMT2A, lysine methyltransferase 2A), as a mechanism to block proleukemogenic signalling. Disrupting the menin-KMT2A axis may also be effective against leukemias harbouring nucleophosmin 1 (NPM1) mutations.
|
|
No information available. |
Summary of Clinical Use ![]() |
Enzomenib (DSP-5336) has progressed to clinical evaluation to determine efficacy as a treatment for acute leukemias with MLL (KMT2A) or or NPM1 gene alterations. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04988555 | A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation | Phase 1/Phase 2 Interventional | Sumitomo Pharma America, Inc. |